What is Cleo Diagnostics Ltd's (COV.AX) StockRank?

MoatMap's StockRank for Cleo Diagnostics Ltd (COV.AX) is 6/100, with a Strong Sell signal. This is a composite score combining Quality (34), Value (22), and Momentum (18) factor ranks across MoatMap's 20,000+ stock universe.

Does Cleo Diagnostics Ltd have an economic moat?

Cleo Diagnostics Ltd (COV.AX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Cleo Diagnostics Ltd a buy, hold, or sell?

MoatMap's current signal for Cleo Diagnostics Ltd (COV.AX) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Cleo Diagnostics Ltd in?

Cleo Diagnostics Ltd (COV.AX) operates in the Healthcare sector, specifically the Medical Devices industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

COV.AX

Strong Sell

Cleo Diagnostics Ltd · Healthcare · Australia · $54M · Avg Vol: $28K/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-109.5%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Cleo Diagnostics Ltd develops and commercializes blood-based diagnostic tests for the early detection of ovarian cancer using novel biomarker technology. The company holds exclusive global rights to a highly accurate, multi-marker diagnostic platform designed to detect ovarian cancer at its earliest stages. It is a clinical-stage medical device company addressing a critical, high-value unmet need in women's oncology diagnostics.

FINANCIAL SUMMARY (AUD)

Year	2023	2024	2025	CAGR	TTM
Revenue	—	—	—	—	—
EPS (AUD)	-0.02	-0.03	-0.03	—	-0.04
Shares	137.1M	128.5M	128.5M	-6.3%	142.4M
Debt	1.6M	—	—	—	—
Equity	-0.9M	10.6M	5.8M	-45.0%	—
Op CF	-0.7M	-2.0M	-2.9M	—	-5.0M
Inv CF	-0.3M	-3.0K	-11.1K	—	—
Fin CF	1.2M	11.2M	0	—	—

Loading 1Y...

PRICE (1Y)-2.8%

SMA 50SMA 200

$0.2472

RSI (14)

51.8

52W High

$0.6448

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-88.8%8.3

ROE

-109.5%9.3

GP/Assets

25.8%57.8

Op. Margin

-330.8%12.4

FCF/Assets

-18.0%23.6

Piotroski

220.4

Int. Cover

—N/A

D/E Ratio

0.00x97.9

Current Ratio

3.80x62.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.7x25.0

P/FCF

—N/A

P/B

9.5x12.3

P/S

29.0x13.4

Div Yield

—N/A

Momentum

52W High %

38%12.3

RS 6M

-37%25.3

SMA 50/200

0.72x9.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$54M

P/E (Forward)

—

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COV.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
COV.AX	Cleo Diagnostics Ltd(you)	$54M	6	Strong Sell
SOM.AX	SomnoMed Limited	$53M	27	Sell
EMV.AX	EMVision Medical Devices Ltd	$111M	14	Strong Sell
PNV.AX	PolyNovo Limited	$515M	33	Sell
4DX.AX	4DMedical Limited	$1.6B	11	Strong Sell
AVR.AX	Anteris Technologies Global Corp.	$861M	26	Sell
IMMP	Immutep Limited	$56M	8	Strong Sell
BOT.AX	Botanix Pharmaceuticals Limited	$51M	9	Strong Sell
IIQ.AX	INOVIQ Ltd	$53M	12	Strong Sell
ALA.AX	Arovella Therapeutics Limited	$53M	14	Strong Sell

Peer medians: ROE -20.6% · P/E 34.6x · Gross margin 61.1%

Cleo Diagnostics Ltd (COV.AX): Stock Score Summary

Cleo Diagnostics Ltd (COV.AX) has a MoatMap StockRank of 6/100 based on Quality (34/100), Value (22/100), and Momentum (18/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$0.25
Market Cap	$54M
Price/Book	9.46
Return on Equity	-109.5%
Return on Invested Capital	-88.8%
Debt/Equity	0.00x
Gross Margin	100.0%
Operating Margin	-330.8%
Revenue Growth	-100.0%
Free Cash Flow	$-861K

Cleo Diagnostics Ltd operates in the Medical Devices industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Cleo Diagnostics Ltd’s (COV.AX) StockRank?: MoatMap’s StockRank for Cleo Diagnostics Ltd (COV.AX) is 6/100, with a Strong Sell signal. It is a composite of Quality (34), Value (22), and Momentum (18) factor ranks across MoatMap’s 20,000+ stock universe.
Does Cleo Diagnostics Ltd have an economic moat?: Cleo Diagnostics Ltd (COV.AX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cleo Diagnostics Ltd a buy, hold, or sell?: MoatMap’s current signal for Cleo Diagnostics Ltd (COV.AX) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Cleo Diagnostics Ltd in?: Cleo Diagnostics Ltd (COV.AX) operates in the Healthcare sector, specifically the Medical Devices industry (Australia).